FDA clears another option for bladder cancer patients

A Johnson & Johnson cancer treatment that can spare certain bladder cancer patients from the radical step of surgical removal of the organ now has FDA approval. J&J's drug/device combination product, Inlexzo, came from the 2019 acquisition of Taris Biomedical.

Editor's Pick

Top Story FDA Nod for J&J's Drug/Device Treatment Gives Bladder Cancer Patients Another Option A Johnson & Johnson cancer treatment that can spare certain bladder cancer patients from the radical step of surgical removal of the organ now has FDA approval. J&J's drug/device combination product, Inlexzo, came from the 2019 acquisition of Taris Biomedical. Sponsored Next-Gen Benefits: Control Costs and Boost Employee Health with Integrated Digital Networks Presented by Solera Health Master the challenge of rising healthcare costs and chronic conditions. Join our webinar to discover how to select and implement digital health solutions that deliver a clear ROI and improve employee outcomes. You'll get actionable strategies to simplify vendor management, boost engagement, and prepare for 2026 benefit planning.  Register Here! Final Call: INVEST Digital Health Kicks Off Next Thursday Doors open in days, don't miss the conversations shaping 2026 strategy. Claim your spot to hear candid insights from leaders, compare notes with peers, and leave with actionable ideas you can use immediately. Register Now

Featured News

Positioning & Distribution Will Determine the Winning Healthcare AI Startups, Investor Says  In a crowded healthcare AI market, the winners will be those that control key leverage points — where data is created, workflows are streamlined and value is delivered across stakeholders. This will differentiate winning AI startups from incumbents and copycat competitors, said Morgan Cheatham, head of healthcare and life sciences at Breyer Capital. A Third of Employers Can't Access Medical Claims Data from Vendors, Survey Finds Many employers are struggling to access their medical claims data from vendors. However, those who do have access are more likely to implement strategies to combat healthcare costs. The Hidden Cost of Healthcare AI: Why Premium Prices Don't Equal Premium Results Now is a good time for health systems to step back and ask some foundational questions instead of rushing into their next AI purchase. Data-Driven Decisions: Unlocking Strategic Financial Performance in Healthcare Data is not optional; it is essential to financial stability and strategic growth. The organizations that thrive will be those that use data to lead, not follow.

Video   Healthcare costs on the rise Employers expect healthcare costs to rise by a median of 9% in 2026, according to a survey by the Business Group on Health. Pharmacy expenses are a key factor.

Sponsored The Top-Rated Suppliers of Lu-177 for Cancer Research Presented by SHINE Technologies With carrier-added and noncarrier-added versions available, the right supplier can make the difference between a program that stalls and one that successfully reaches patients. Learn More.

Resources

MedCity FemFwd: Designing Healthcare Spaces for Women In this episode, we're joined by Abbie Clary, executive director of Health for All for CannonDesign, an architecture design company. She discusses why healthcare traditionally hasn't been built around women, and what needs to change. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe